SLXN

$0.15+0.10%visit website

Silexion Therapeutics Corp

Market Cap

$2M

Finnhub, as of 2026-10-17

Sector

Health Care

Industry

Biotechnology

Beta (raw)

3.26

60mo monthly vs SPY

P/E (TTM)

—

Price / TTM diluted EPS

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

—

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	2,157	3,375	1,370	2,212	9,114
Total operating expenses	3,292	4,406	2,749	3,680	14,127
Operating income	(3,292)	(4,406)	(2,749)	(3,680)	(14,127)
Pretax income	(3,262)	(4,412)	(2,733)	(3,551)	(13,958)
Income tax	0.00	0.00
Net income	(3,262)	(4,412)	(2,733)	(3,551)	(13,958)
EPS (basic) ($)	2.88		6.80	5.17	—
EPS (diluted) ($)	2.88		6.80	5.17	—
Weighted avg. shares (basic)	1,133		404	687
Weighted avg. shares (diluted)	1,133		404	687

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 14, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 9 more quarters, back to Jun 2023, with Tormere Pro.